TY  - JOUR
T1  - No place for novel oral anticoagulants in current treatment of acute coronary syndromes: Comment on “use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome”
AU  - Hernandez AV
Y1  - 2012/11/12
N1  - 10.1001/2013.jamainternmed.293
JO  - Archives of Internal Medicine
SP  - 1546
EP  - 1547
VL  - 172
IS  - 20
N2  - 
In contrast to warfarin, novel oral anticoagulants (NOACs), such as direct thrombin inhibitors and anti-Xa, do not require monitoring and have minimal food and drug interactions. Moreover, compared with warfarin NOACs have demonstrated significant reductions in thrombotic events and lower rates of major bleeding events in patients having atrial fibrillation and in patients undergoing knee and hip surgery.3 In recent years, several phase 2 and phase 3 trials of NOACs for the treatment of patients with ACS have been published, with most of the patients receiving dual antiplatelet treatment. Although recent detailed review articles have described the pros and cons of the use of NOACs in ACS,4- 5 the available evidence has not been quantitatively summarized.

SN  - 0003-9926
M3  - doi: 10.1001/2013.jamainternmed.293
UR  - http://dx.doi.org/10.1001/2013.jamainternmed.293
ER  -